Tandem Diabetes Care (TNDM) Common Equity (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Common Equity for 14 consecutive years, with $130.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 2.17% year-over-year to $130.4 million; the trailing twelve-month figure through Jun 2026 stood at $130.4 million (down 2.17% YoY), and the FY2025 full-year result was $155.2 million, down 41.02% from the prior year.
• Common Equity slipped to $130.4 million in Q2 2026 per TNDM's latest filing, from $132.4 million in the prior quarter.
• Across five years, Common Equity topped out at $449.6 million in Q2 2022 and bottomed at $130.4 million in Q2 2026.
• Historically, Common Equity has averaged $270.1 million across 5 years, with a median of $253.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 39.55% in 2022, then sank 44.06% in 2025.
• Over 5 years, Common Equity stood at $439.9 million in 2022, then declined by 28.71% to $313.6 million in 2023, then dropped by 16.11% to $263.1 million in 2024, then plunged by 41.02% to $155.2 million in 2025, then declined by 15.97% to $130.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $130.4 million, $132.4 million, and $155.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.